Legend Biotech Corporation (NASDAQ LEGN) presented today new and updated results from the CARTITUDE clinical development program studying ciltacabtagene Autoleucel. Overall response rate remains at 98 percent after more than two years, with median progression-free and overall survival not yet being reached.
🌍 Legend Biotech (LEGN) - Form 6-K Filing
Filing Date: 2022-06-06
Accepted: 2022-06-06 06:00:19
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: